In Dec. 2024, Quoin received FDA clearance to initiate a new investigator led whole-body clinical study for QRX003, which will evaluate the safety and efficacy of twice-daily application of QRX003 to more than 80% of the body surface area in NS patients, an application dosage QNRX anticipates in real-world usage if QRX003 obtains regulatory approval. This represents the most extensive clinical application of QRX003 thus far. QNRX expects its cash / equivalents balance to be sufficient to fund operations into 2Q26 & remains optimistic about QRX003's prospects to be the first approved treatment for NS.
